PEN-FAST Penicillin Allergy Score
ورودیهای بالینی بیمار
پارامترهای بالینی بیمار را در فرم روبرو وارد کنید و روی «محاسبه» کلیک نمایید تا نمره، طبقه خطر و اقدامات فوری نمایش داده شوند.
- Very low0–0
- Low1–2
- Moderate3–3
- High4–5
The PEN-FAST Penicillin Allergy Score calculates predicting invasive bacterial infection probability and quantifying systemic host response to sepsis. Key inputs include recent 5y. Scores guide administering empiric broad-spectrum antimicrobial regimens, infectious source control, and isolation protocols. This standardized assessment improves clinical decision safety and bedside patient management.
Clinical Guidelines & Evidence
PEN-FAST penicillin allergy risk score (Trubiano 2020) for de-labeling: allergy in last 5 years (2), anaphylaxis/angioedema (2), severe cutaneous adverse reaction (2), treatment required (1); total 0-5. 0 very low, 1-2 low, 3 moderate, 4-5 high risk.
Clinical Indication
The PEN-FAST Penicillin Allergy Score is indicated for bedside clinical practice to support PEN-FAST penicillin allergy risk score (Trubiano 2020) for de-labeling: allergy in last 5 years (2), anaphylaxis/angioedema (2), severe cutaneous adverse reaction (2), treatment required (1); total 0-5. 0 very low, 1-2 low, 3 moderate, 4-5 high risk.. It assists healthcare providers in standardizing clinical assessment and therapeutic decision-making.
Target Population
Target population comprises Patients presenting with suspected sepsis, meningitis, pneumonia, COVID-19, opportunistic infections, or fever of unknown origin. Clinical application is indicated across Infectious disease services, septic shock bays, febrile illness clinics, and isolation units.
Limitations & Contraindications
Timely administration of empiric antibiotic therapy in suspected septic shock must never be delayed for score tabulation.
Clinical Pearls & Action Plan
Blood and site-specific microbiological cultures should be secured prior to administering broad-spectrum antimicrobials.
PEN-FAST = F(2) + A(2) + S(2) + T(1).
Input Parameters
| Name | Type | Required | Description |
|---|---|---|---|
| recent_5y | string | Yes | Allergy reported within the last 5 years |
| anaphylaxis_angioedema | string | Yes | Anaphylaxis or angioedema |
| scar | string | Yes | Severe cutaneous adverse reaction (SJS/TEN/DRESS) |
| treatment_required | string | Yes | Treatment required for the reaction |
Score Interpretation & Guidance
| Range | Stage | Description |
|---|---|---|
| 0–0 | Very low | Very low risk |
| 1–2 | Low | Low risk |
| 3–3 | Moderate | Moderate risk |
| 4–5 | High | High risk |
Evidence-Based References (EBM)
- Trubiano JA, Vogrin S, Chua KYL, et al. Development and validation of a penicillin allergy clinical decision rule. JAMA Intern Med. 2020;180(5):745-752.